Integra Lifesciences
IART
13.00
0.00
0.00%
Integra Lifesciences
US · IART
#3240 by market cap
13.00
0.00
0.00%
Live - 5344 symbols - heartbeat 27s ago
· 2026-10-08 10:11
Pre-market
13.02
+0.15%
After-hours
13.00
0.00%
- Market cap
- 1.01B
- P/E (TTM)i
- -144.44
- P/Bi
- 0.97
- EPSi
- -6.74
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on IART?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 0.2 percentage points.
Institutional ownership
- Held by institutions
- 106.73% +0.22pp
- Institutions
- 258
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund74.24%
Hedge Fund15.96%
Private Company11.52%
Individual/Insider3.63%
Public Company3.26%
Government Pension Fund1.33%
Insurance Company0.32%
Top holders as of 2026-06-30
BlackRock
13.74% · 10.68M sh
Tru St Partnership LP
10.95% · 8.52M sh
Rubric Capital Management LP
9.97% · 7.75M sh
Vanguard Portfolio Management, LLC
4.81% · 3.74M sh
Invesco Ltd.
4.43% · 3.44M sh
Paradigm Capital Management, Inc.
4.42% · 3.44M sh
Fuller & Thaler Asset Management, Inc.
4.42% · 3.44M sh
Vanguard Capital Management, LLC
4.36% · 3.39M sh
Eaton Vance Management
4.15% · 3.23M sh
State Street Global Advisors
3.79% · 2.95M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| Tru St Partnership LP | -- | 10.95% |
| Stuart Essig | Independent Chairperson | 2.30% |
| Barbara Hill | Independent Director | 0.24% |
| Mojdeh Poul | Chief Executive Officer | 0.13% |
| Christian Schade | Independent Director | 0.12% |
| Keith N. Bradley | Independent Director | 0.11% |
| Raymond Murphy | Independent Director | 0.11% |
| Robert Davis | Executive VP & President of Tissue Technologies | 0.09% |
| Michael McBreen | Executive VP & President of Codman Specialty Surgical | 0.08% |
| Eric Schwartz | Executive Vice President | 0.07% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | Lesha Shinn | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-31 | Chantal Veillon-Berteloot | Executive Vice President | Sale to Issuer | -1,455 | $16.62 |
| 2026-07-02 | Lea Knight | Chief Financial Officer | Sale to Issuer | -5,226 | $18.05 |
| 2026-06-30 | Robert Davis | Executive VP & President of Tissue Technologies | Other Derivative Acquisition | +11,180 | -- |
| 2026-06-30 | Jeffrey Mosebrook | Senior VP & PAO | Sale to Issuer | -937 | $17.89 |
| 2026-06-30 | Harvinder Singh | Executive VP & President of International Business | Other Derivative Acquisition | +5,590 | -- |
| 2026-05-31 | Stuart Essig | Independent Chairperson | Other Derivative Acquisition | +365,297 | -- |
| 2026-05-31 | Stuart Essig | Independent Chairperson | Other Derivative Acquisition | +705,468 | $15.67 |
| 2026-05-31 | Michael McBreen | Executive VP & President of Codman Specialty Surgical | Other Derivative Acquisition | +31,909 | -- |
| 2026-05-31 | Michael McBreen | Executive VP & President of Codman Specialty Surgical | Other Derivative Acquisition | +60,372 | $15.67 |
| 2026-05-08 | Keith N. Bradley | Independent Director | Sale to Issuer | -882 | $13.92 |
| 2026-05-06 | Christian Schade | Independent Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-05-06 | Barbara Hill | Independent Director | Other Acquisition | +24,338 | -- |
| 2026-05-06 | Keith N. Bradley | Independent Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-05-06 | Jeffrey Graves | Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-05-06 | Shaundra Clay | Independent Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-05-06 | Renee Lo | Independent Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-03-10 | Robert Davis | Executive VP & President of Tissue Technologies | Sale to Issuer | -9,174 | $9.55–9.61 |
| 2026-03-10 | Robert Davis | Executive VP & President of Tissue Technologies | Other Derivative Acquisition | +43,350 | -- |
| 2026-03-10 | Mojdeh Poul | Chief Executive Officer | Other Derivative Acquisition | +343,393 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:11:00 · For reference only, not investment advice and not tailored to your situation.